Based on different duration of extended consolidation therapy, 96 patients were divided into 3 groups (Group1: extended 1–12 mon, 54 patients; Group2: extended12–24 mon, 23 patients; Group3: extended 24–36 mon, 19 patients). All parameters were collected after cessation of NAs treatment. The relapse was defined as HBV DNA > 1.0*103copies/ml. Results: The cumulative relapse rates of group A and group B after withdrawal of NAs treatment in 6, 12, 18, 24, 36 Epigenetics inhibitor and 48 months were 52.5%vs29.2%, 72.5%vs35.4%, 75.0%vs37.5%, 77.5%vs39.6%,

80.0%vs41.7% and 82.5%vs41.7%. The cumulative relapse rates of three subgroups were 38.8%, 50.0%, 51.9%, 53.7%, 53.7% and 53.7% in Group 1; 17.4%, 17.4%, 21.7%, 26.1%, 30.4% and 30.4% in Group 2; 15.8%, 15.8%, 15.8%, 15.8% and 21.1% in group. The relapse rate of Group 1 was the highest, the following was of Group 2, and of Group 3 was the lowest one. Conclusion: CHB patients treatmented

with longer duration of extended consolidation therapy after meeting NAs cessation criteria may have the lower relapse rates GSK2118436 mouse after withdrawal of NAs. Key Word(s): 1. Chronic Hepatitis B; 2. Consolidation; 3. Withdrawal; 4. Relapse; Presenting Author: ZHANG QIAN Additional Authors: WENQIAN QI, SHAOYOU QIN, YAN XU, YONGGUI ZHANG, XU WANG, YAN LI, PING ZHAO, HONGHUA GUO, JIAN JIAO, CHANGYU ZHOU, JIANGBIN WANG Corresponding Author: ZHANG QIAN, JIANGBIN WANG Affiliations: China-Japan Union hospital of JiLin University Objective: To estimate the prevalence hepatic Steatosis in HBV infection in northern china and to determine risk factors. Methods: Datas were collected from medical groups of 3rd hospital of jilin university in Jilin Province, China. Questionnaires were used to obtain socio-demographic data. HBsAg, HBsAb, HBeAb, HBeAb, HBcAb and anti-HCV were detected by enzyme immunoassays. Patients with HBsAg/anti-HCV Edoxaban positive were tested by Color Doppler, liver enzymes

and HBV DNA/ HCV RNA, HBV DNA /RNA genotype, IL 28B. To identify risk factors. Results: The prevalence of Steatosis in HCV was 27.33%, which was significant higher than the one in HBV (14.98%), and the steatosis in none HBV or HCV infection was 9.76%. And it was highest in HCV among 45–65 years old patients, however it was highest in HBV among 35–55 years old patients. HCV RNA level and positive rate was significant higher in steatosis co HCV than HCV infection, however this was no significant in steatosis co HBV and HBV infection. Steatosis in HBV or HCV was significantly associated with BMI > 25, Diabetes, hypertriglyceridemia and hypercholesterolemia. Conclusion: The prevalence of steatosis in HCV was signicicant higher than HBV, and higher than no HBV or HCV infection in the northern of China. Risk factors of steatosis in HBV or HCV infection were BMI > 25, Diabetes, hypertriglyceridemia and hypercholesterolemia. Key Word(s): 1. hepatic Steatosis; 2. Epidemiology; 3. HBV; 4.